Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? (Q35951845)

11 August 2017

1 reference

title

Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? (English)

1 reference

11 August 2017

0 references

Evangelos Andreakos

1

1 reference

11 August 2017

Brian Foxwell

series ordinal

2

1 reference

11 August 2017

Marc Feldmann

series ordinal

3

1 reference

11 August 2017

publication date

1 December 2004

1 reference

11 August 2017

published in

Immunological Reviews

1 reference

11 August 2017

volume

202

1 reference

11 August 2017

page(s)

250-265

1 reference

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

An interleukin 1 like factor stimulates bone resorption in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

A toll-like receptor that prevents infection by uropathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The extra domain A of fibronectin activates Toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

mRNA is an endogenous ligand for Toll-like receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Genomic DNA released by dying cells induces the maturation of APCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Dendritic-cell control of pathogen-driven T-cell polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

MyD88: An Adapter That Recruits IRAK to the IL-1 Receptor Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

MyD88, an adapter protein involved in interleukin-1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

IRAK-M is a negative regulator of Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Identification of Lps2 as a key transducer of MyD88-independent TIR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

The Toll-IL-1 receptor adaptor family grows to five members.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Triggering the interferon antiviral response through an IKK-related pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Crosstalk between LXR and Toll-like Receptor Signaling Mediates Bacterial and Viral Antagonism of Cholesterol Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Broad expression of Toll-like receptors in the human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Toll-like receptor 4 polymorphism and severity of atopy in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Toll-like Receptor 4 Polymorphisms and Atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

Mutations in the gene for toll-like receptor 4 and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.0105-2896.2004.00202.X

10.1111/J.0105-2896.2004.00202.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference